Agilent xCELLigence RTCA instrumentation applied in recent FDA approval

Agilent (A) Technologies announces its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL, a recently approved CAR T therapy. Agilent’s advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis RTCA rtechnology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. The xCELLigence Real-Time Cell Analysis RTCA technology is a cutting-edge platform that continuously monitors cell behavior in real-time without using labels or dyes. This technology measures electrical impedance to provide dynamic information on cell numbers, viability, and morphology. Unlike traditional endpoint assays, xCELLigence RTCA offers real-time insights, enabling more accurate and timely decision-making in drug development. Its ability to deliver continuous, real-time data sets it apart in the market, providing researchers with a deeper understanding of cellular responses and enhancing the development of effective therapies. ..Agilent is committed to advancing scientific innovation and supporting groundbreaking therapies that enhance health outcomes. To learn more about Agilent’s real-time cell analysis solutions, visit Agilent Cell Analysis.